John H. Krystal, M.D.
"Glutamate Synaptic Dysfunction in Schizophrenia: Microcircuits, Macrocircuits, and Novel Therapeutics”
Laureate Psychiatric Clinic and Hospital Conference Center
9:00am - 9:45 am Registration and Breakfast, breakfast stops being served at 9:45 - no exceptions
10:00am - 11:00am Program
Dr. Krystal is the Robert L. McNeil, Jr., Professor of Translational Research, Chair of the Department of Psychiatry, and Professor of Neuroscience at the Yale University School of Medicine and Chief of Psychiatry at Yale-New Haven Hospital. He is a graduate of the University of Chicago, Yale University School of Medicine, and the Yale Psychiatry Residency Training Program. He has published extensively on the neurobiology and treatment of schizophrenia, alcoholism, PTSD, and depression. Notably, he led the discovery of the rapid antidepressant effects of ketamine in humans. He is the Director of the NIAAA Center for the Translational Neuroscience of Alcoholism and the Clinical Neuroscience Division of the VA National Center for PTSD. Dr. Krystal is a member of the U.S. National Academy of Medicine. Currently, he is president of the International College of Neuropsychopharmacology (CINP), a member of the NIMH National Mental Health Advisory Council, and editor of Biological Psychiatry (IF=11.212).
Learning points:
1. To introduce glutamate synaptic dysfunction in schizophrenia
2. To describe evidence for disinhibited/hyperconnected and atrophic phases of schizophrenia
3. To consider the implications of these pathophysiologic hypotheses for glutarnatergic pharmacotherapies for schizophrenia
REGISTER TO ATTEND!
To register, email: Lauren Haguewood at lehaguewood@saintfrancis.com
"Glutamate Synaptic Dysfunction in Schizophrenia: Microcircuits, Macrocircuits, and Novel Therapeutics”
Laureate Psychiatric Clinic and Hospital Conference Center
9:00am - 9:45 am Registration and Breakfast, breakfast stops being served at 9:45 - no exceptions
10:00am - 11:00am Program
Dr. Krystal is the Robert L. McNeil, Jr., Professor of Translational Research, Chair of the Department of Psychiatry, and Professor of Neuroscience at the Yale University School of Medicine and Chief of Psychiatry at Yale-New Haven Hospital. He is a graduate of the University of Chicago, Yale University School of Medicine, and the Yale Psychiatry Residency Training Program. He has published extensively on the neurobiology and treatment of schizophrenia, alcoholism, PTSD, and depression. Notably, he led the discovery of the rapid antidepressant effects of ketamine in humans. He is the Director of the NIAAA Center for the Translational Neuroscience of Alcoholism and the Clinical Neuroscience Division of the VA National Center for PTSD. Dr. Krystal is a member of the U.S. National Academy of Medicine. Currently, he is president of the International College of Neuropsychopharmacology (CINP), a member of the NIMH National Mental Health Advisory Council, and editor of Biological Psychiatry (IF=11.212).
Learning points:
1. To introduce glutamate synaptic dysfunction in schizophrenia
2. To describe evidence for disinhibited/hyperconnected and atrophic phases of schizophrenia
3. To consider the implications of these pathophysiologic hypotheses for glutarnatergic pharmacotherapies for schizophrenia
REGISTER TO ATTEND!
To register, email: Lauren Haguewood at lehaguewood@saintfrancis.com
RSS Feed